Effect Of Abdominal Hypopressive Training On Stress Urinary Incontinence

Effect Of Abdominal Hypopressive Training On Stress Urinary IncontinenceIn Female Athletes

Fifty female athletes suffering from stress incontinence (SUI) will participate in this study. They will be selected from El Zohour Club, New Cairo City.

Study Overview

• Status: Completed
• Conditions: Female Stress Urinary Incontinence
• Intervention / Treatment: Other: pelvic floor exercises, nutritional instructions; Other: abdominal hypopressive exercises, pelvic floor exercises, nutritional instructions

Detailed Description

They will be randomly distributed into 2 groups equal in numbers:

Group (A) (Control group) consists of 25 female athletes. They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.

Group (B) (Study group) consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.

Before data collection, the purpose and procedures will be fully explained to the females. Informed consent will be obtained from each female. Each female will be evaluated following a standard protocol.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Phase 2

Contacts and Locations

Study Locations

• Egypt
  • Cairo
    • New Cairo, Cairo, Egypt, 470001
      • El Zohour Club

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Female athletes suffering from SUI.
2. They will be diagnosed with SUI using bladder stress test.
3. Their ages will range from 14-18 years old.
4. Their body mass index (BMI) will range from 18.5-24.9 kg/m2.
5. They are single females.

Exclusion Criteria:

The female athlete will be excluded if they had:

1. Urinary tract infection.
2. Family history of genito-urinary tract cancer.
3. Diabetes mellitus.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Group (A) (Control group); consists of 25 female athletes. They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.	Other: pelvic floor exercises, nutritional instructions; They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.
Experimental: Group (B) (Study group); consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.	Other: abdominal hypopressive exercises, pelvic floor exercises, nutritional instructions; consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of urine loss	Pad testing will be used to quantify the volume of urine loss by weighing an absorbent pad before and after some type of leakage provocation. The test will start with weighting clean empty pad in grams. Then, it will be used until next time and weighted again. The weight of the used pad will be subtracted from the weight of the empty pad so the net result will determine the amount of leakage.	24 hours pad test for12 weeks
assesment of pelvic floor muscle contraction and tonning	The measurements will be taken in crock-lying position with a full bladder, neutral lumbar spine. The ultrasound transducer will be inserted transversely directly superior to the symphysis pubis, probe is tilted 60 degrees from vertical (Arab, 2010). Every female will perform 3 maximal PFM contractions so that displacement of the bladder wall, because of a PFM contraction, could be measured.	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of symptoms and health related quality of life	The ICIQ-SF will be used in assessment of each female in both groups. It is used to measure severity and impact of UI on the quality of life in women. The ICIQ-SF is formed of six items of which four main items ask for rating of UI symptoms in the past 4 weeks. A score of zero means no leakage of urine and no affection on quality of life. (Question 1): quantifies the frequency of urinary leaking, (question 2): evaluates the amount of leaking and (question 3): how much the urinary incontinence interferes with everyday life (Hilton and Robinson, 2011). The scores for items 3, 4 and 5 are taken for the final ICIQ-SF score. Items 1 and 2 are demographic and the final item is a self-diagnostic item for the type of UI. ICIQ- SF (range 0-21) is given four scoring categories: slight (1-5), moderate (6-12), severe (13-18) and very severe (19-21).	12 weeks

Collaborators and Investigators

• Sponsor: Badr University
• Collaborators: Cairo University
• Investigators: Study Chair: Abeer ElDeeb, Professor, PROFESSOR DOCTOR

Study record dates

Study Major Dates

• Study Start (Actual): August 20, 2024
• Primary Completion (Actual): November 20, 2024
• Study Completion (Actual): December 22, 2024

Study Registration Dates

• First Submitted: August 18, 2024
• First Submitted That Met QC Criteria: September 13, 2024
• First Posted (Actual): September 19, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 4, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Keywords: stress incontinence, and female athelete
• Additional Relevant MeSH Terms: Urogenital Diseases; Mental Disorders; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urination Disorders; Lower Urinary Tract Symptoms; Urological Manifestations; Behavioral Symptoms; Elimination Disorders; Urinary Incontinence; Enuresis; Urinary Incontinence, Stress
• Other Study ID Numbers: P.T.REC/012/004947

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: not sharing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No